These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21416695)

  • 41. Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects.
    Mehta PK; Simpson L; Lee EK; Lyle TA; McConnell ME; Book WM
    Tex Heart Inst J; 2008; 35(3):256-61. PubMed ID: 18941642
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists.
    Kenna JG; Stahl SH; Eakins JA; Foster AJ; Andersson LC; Bergare J; Billger M; Elebring M; Elmore CS; Thompson RA
    J Pharmacol Exp Ther; 2015 Feb; 352(2):281-90. PubMed ID: 25467130
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sitaxsentan in pulmonary arterial hypertension.
    Apostolopoulou SC; Rammos S
    Chest; 2003 May; 123(5):1772; author reply 1772-3. PubMed ID: 12740304
    [No Abstract]   [Full Text] [Related]  

  • 44. Pulmonary hypertension in older children: new approaches and therapies.
    Abman SH
    Paediatr Respir Rev; 2006; 7 Suppl 1():S177-9. PubMed ID: 16798555
    [No Abstract]   [Full Text] [Related]  

  • 45. Sitaxentan: in pulmonary arterial hypertension.
    Scott LJ
    Drugs; 2007; 67(5):761-70; discussion 771-2. PubMed ID: 17385944
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sitaxsentan therapy for pulmonary arterial hypertension.
    Barst RJ; Langleben D; Frost A; Horn EM; Oudiz R; Shapiro S; McLaughlin V; Hill N; Tapson VF; Robbins IM; Zwicke D; Duncan B; Dixon RA; Frumkin LR;
    Am J Respir Crit Care Med; 2004 Feb; 169(4):441-7. PubMed ID: 14630619
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases.
    Humbert M; Simonneau G
    Nat Clin Pract Rheumatol; 2005 Dec; 1(2):93-101. PubMed ID: 16932638
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An update on the use of ambrisentan in pulmonary arterial hypertension.
    D'Alto M
    Ther Adv Respir Dis; 2012 Dec; 6(6):331-43. PubMed ID: 22933513
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension.
    Rubin LJ
    Life Sci; 2012 Oct; 91(13-14):517-21. PubMed ID: 22884806
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Specific drugs for the treatment of pulmonary arterial hypertension - current status].
    Stähler G
    Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S183-6. PubMed ID: 18814092
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The importance of sex in pulmonary hypertension.
    Rich S
    Chest; 2012 Jan; 141(1):4-5. PubMed ID: 22215821
    [No Abstract]   [Full Text] [Related]  

  • 52. CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 polymorphisms in patients with bosentan-induced liver toxicity.
    Roustit M; Fonrose X; Montani D; Girerd B; Stanke-Labesque F; Gonnet N; Humbert M; Cracowski JL
    Clin Pharmacol Ther; 2014 Jun; 95(6):583-5. PubMed ID: 24842639
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An evidence-based approach to the management of pulmonary arterial hypertension.
    Coyne TC
    Curr Opin Cardiol; 2006 Sep; 21(5):526; author reply 526-7. PubMed ID: 16900019
    [No Abstract]   [Full Text] [Related]  

  • 54. Bioactivation of sitaxentan in liver microsomes, hepatocytes, and expressed human P450s with characterization of the glutathione conjugate by liquid chromatography tandem mass spectrometry.
    Erve JC; Gauby S; Maynard JW; Svensson MA; Tonn G; Quinn KP
    Chem Res Toxicol; 2013 Jun; 26(6):926-36. PubMed ID: 23721565
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan.
    Benza RL; Mehta S; Keogh A; Lawrence EC; Oudiz RJ; Barst RJ
    J Heart Lung Transplant; 2007 Jan; 26(1):63-9. PubMed ID: 17234519
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature.
    Eriksson C; Gustavsson A; Kronvall T; Tysk C
    J Gastrointestin Liver Dis; 2011 Mar; 20(1):77-80. PubMed ID: 21451802
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Endothelin receptor antagonists in pulmonary arterial hypertension.
    Dupuis J; Hoeper MM
    Eur Respir J; 2008 Feb; 31(2):407-15. PubMed ID: 18238950
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade.
    Zacà V; Metra M; Danesi R; Lombardi C; Verzura G; Dei Cas L
    Ther Adv Respir Dis; 2009 Feb; 3(1):11-4. PubMed ID: 19293198
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pulmonary hypertension: basic concepts and practical management.
    Hoeper MM; Dinh-Xuan AT
    Eur Respir J; 2008 Feb; 31(2):236-7. PubMed ID: 18238945
    [No Abstract]   [Full Text] [Related]  

  • 60. Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension.
    Miyagawa K; Emoto N
    Ther Adv Cardiovasc Dis; 2014 Oct; 8(5):202-16. PubMed ID: 24990369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.